Treating Triple-Negative Breast Cancer

Slideshow

This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Related Content
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Survival Outcomes Improve With TIL Presence in TNBC

April 16th 2024
Article

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

November 15th 2017
Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

February 13th 2024
Article

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

April 7th 2017
Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC

December 7th 2023
Article

Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.

Pembrolizumab/Chemo Improves EFS Vs Chemo in High-Risk TNBC

October 20th 2023
Article

Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.